GlassScriptPhysician profile
Aruna Baratham
NPI 1518989557
$22,844.07
in general payments reported to CMS, 2019-2025
51 companies · $4,764 in 2025
The $4,764 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $1,730 · 2021: $2,672 · 2022: $3,117 · 2023: $4,127 · 2024: $4,484 · 2025: $4,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,086.40 |
| Education | $288.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,108.74 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,690.21 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Astrazeneca Pharmaceuticals LP | $1,947.06 | 2019-2025 | Saphnelo, Tezspire, Breztri |
| Janssen Biotech, INC. | $1,475.47 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $1,396.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,231.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,081.38 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $950.33 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $815.82 | 2019-2025 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $793.20 | 2021-2025 | Acthar |
| Csl Behring | $774.63 | 2019-2025 | Hizentra, Haegarda, Kcentra |
| Regeneron Healthcare Solutions, INC. | $770.68 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $752.80 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| E.R. Squibb & Sons, L.L.C. | $725.09 | 2019-2025 | Orencia |
| Genentech USA, INC. | $707.96 | 2019-2025 | Actemra, Xolair |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Baratham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.